Lorenzo Rossaro

Medicine · Health Sciences

38h-index7.6kcitations140works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(59), Liver Disease and Transplantation(50), Hepatitis C virus research(43), Organ Transplantation Techniques and Outcomes(28), Hepatitis B Virus Studies(19)

Publications140 total

Association of FDA Mandate Limiting Acetaminophen (Paracetamol) in Prescription Combination Opioid Products and Subsequent Hospitalizations and Acute Liver Failure
JAMA·2023· 27 citedOpen Access
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial
Evidence-based Complementary and Alternative Medicine·2022· 16 citedOpen Access
A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure
Journal of Hepatology·2021· 41 citedOpen Access
Clinical and Neurologic Outcomes in Acetaminophen-Induced Acute Liver Failure: A 21-Year Multicenter Cohort Study
Clinical Gastroenterology and Hepatology·2020· 38 citedOpen Access
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
PLoS ONE·2020· 5 citedOpen Access
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir‐experienced, <scp>NS</scp>5A treatment‐naïve patients: Findings from two randomized trials
Liver International·2017· 13 cited
The Natural History of Severe Acute Liver Injury
The American Journal of Gastroenterology·2017· 137 citedOpen Access
Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the <scp>OT</scp>‐0401 and <scp>REVERSE</scp> randomised clinical studies
Alimentary Pharmacology & Therapeutics·2017· 100 citedOpen Access
Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver Injury
Cellular and Molecular Gastroenterology and Hepatology·2017· 12 citedOpen Access
Efficacy and safety of ledipasvir/sofosbuvir, with or without ribavirin, for treatment of hepatitis C virus-mono and HCV/HIV co-infected patients who have failed prior treatment with non-NS5A, SOF-based therapies
Journal of Hepatology·2017
HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death
Clinical Gastroenterology and Hepatology·2016· 38 citedOpen Access
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities
Clinical Gastroenterology and Hepatology·2016· 27 cited
Outcomes in Adults With Acute Liver Failure Between 1998 and 2013
Annals of Internal Medicine·2016· 373 citedOpen Access
Tu1687 Sofosbuvir Plus Ribavirin for 12 Weeks in Genotype 2 HCV Compensated Cirrhotic Patients; A Comparative Analysis of VALOR-HCV SVR Data to Registration Trials and Real World Cohorts
Gastroenterology·2016
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1
Gastroenterology·2016· 302 citedOpen Access
Association Between Plasma Level of Galectin-9 and Survival of Patients With Drug-Induced Acute Liver Failure
Clinical Gastroenterology and Hepatology·2015· 20 cited
Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B)
HAL (Le Centre pour la Communication Scientifique Directe)·2014· 3 cited
Building the Multidisciplinary Team for Management of Patients With Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology·2014· 54 citedOpen Access
764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study
Gastroenterology·2014· 3 cited
Sa1319 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis (S-USIIT-01)
Gastroenterology·2014· 9 cited
page 1 of 7Next →

Frequent Co-authors

K. Rajender Reddy(11), William M. Lee(11), Robert J. Fontana(10), Constantine Karvellas(10), Brendan M. McGuire(8), Anne M. Larson(7), Natalie Murray(7), Timothy M. McCashland(7), Andrés T. Blei(6), Adrian Reuben(6), Oren K. Fix(6), Michael L. Schilsky(6), J. Eileen Hay(6), Obaid S. Shaikh(6), Daniel Ganger(6), Atif Zaman(6), Santiago J. Muñoz(6), Raj Satyanarayana(6), Tarek Hassanein(6), Ram Subramanian(6)